Business
Radiopharm Theranostics tanks on ASX debut – The Australian Financial Review
The paper value of chairman Paul Hopper’s 35.5 per cent stake fell from $54 million to $36 million in just a few hours.
The early stage company does not have revenue from licence arrangements or product sales. It is developing a platform of radiopharmaceutical products for diagnostic and therapeutic cancer treatment.
Shanghai-based NanoMab Technologies is the second-largest…
Continue Reading
-
Business24 hours agoWhy Amotiv, Breville, Life360, and Woodside shares are tumbling today
-
Noosa News22 hours agoDevastating update in search for missing Queensland mother Tayla Spies as police find human remains near her ute
-
General22 hours agoHousing affordability. The crisis the major parties are too scared to fix
-
Business20 hours agoASX 200 plunges as US tariffs fall-out continues